久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

USEUROPEAFRICAASIA 中文雙語Fran?ais
Opinion
Home / Opinion / Op-Ed Contributors

How to fight antimicrobial resistance globally

By Jorg Reinhardt | China Daily | Updated: 2017-07-31 06:47

How to fight antimicrobial resistance globally

LUO JIE/CHINA DAILY

Three weeks ago, G20 leaders committed to working together to address one of the world's most pressing and perplexing security threats: antimicrobial resistance (AMR)-a fierce and evolving adversary against which conventional therapeutic weapons are of no use.

The threat is straightforward: bacteria and other microbes are becoming resistant to available medicines faster than new medicines are being developed. Every year, drug-resistant microbes kill about 700,000 people worldwide-more than three times the annual death toll from armed conflicts.

Last year, a special panel commissioned by the British government predicted that, by 2050, as many as 10 million more people will die from drug-resistant microbes every year. AMR now poses a clear danger to every person on the planet. Unless we confront it head-on, we could return to a world in which it is common for people to die from basic infections.

Beyond the cost in human lives, AMR could devastate the world's economies. In Europe alone, the annual healthcare costs and productivity losses associated with AMR already total about 1.5 billion euros ($1.7 billion).

The G20, for its part, has taken an important step forward: each G20 country has promised to start implementing national plans to fight AMR in earnest, and to do more to promote new treatments against resistant microbes. To that end, G20 leaders are calling for an international "research and development collaboration hub" to "maximize the impact of existing and new anti-microbial basic and clinical research initiatives". And they have promised to explore how market incentives can be used to encourage new research.

Beyond the G20, innovative public-private partnerships are emerging to deliver new treatments against drug-resistant killers such as tuberculosis. And some governments have already started filling critical roles in the global response to AMR, by collecting data on the spread of resistant strains of E. coli, salmonella and other common pathogens.

Now it is up to political leaders to follow through on their commitments. Because new treatments for multidrug-resistant microbes aren't expected to generate much return on investment, it is incumbent upon governments to make research and development in this field more attractive to private companies, and, in order to stem the development of resistance, to ensure that new drugs are not overused.

Besides, more well-funded collaborations between governments and private institutions are needed. When private institutions enter into such collaborative efforts, they must be prepared to work outside of traditional boundaries, accept the challenges associated with complex public projects, and be willing to bring their skills, ideas and experience to the table.

In responding to AMR, we can learn some valuable lessons from other global public health efforts. Malaria, which is caused by a parasite transmitted by more than 100 species of Anopheles mosquito, is a leading cause of death in many parts of the world. But its death toll has been halved over the last 15 years thanks to the high priority accorded to fighting the disease by many governments and private institutions.

Still, the parasite that causes malaria is developing resistance to artemisinin, which forms the basis for the most effective treatment: artemisinin-based combination therapies. Artemisinin resistance first emerged in Cambodia just over a decade ago, and has since spread through Thailand, Laos, Vietnam, Myanmar and China. It is now approaching India, and experts fear it will eventually reach Africa. According to one recent study, if artemisinin resistance is allowed to spread, malaria will kill at least 116,000 more people every year.

Unless new treatments become available, the tremendous progress that the world has made against malaria will have been tragically short-lived. Fortunately, those engaged in the global response to malaria recognize that just as parasites are adapting to new situations, so must we. New efforts are underway to identify and minimize the spread of resistant malaria, while simultaneously developing new artemisinin-free treatments.

For example, the Regional Artemisinin-Resistance Initiative is working to halt the spread of resistant malaria in the Mekong Delta region, by monitoring and sharing drug-resistance data and promoting proper use of antimalarial treatments. So far, the initiative has secured $128.65 million through the Global Fund to Fight AIDS, Tuberculosis and Malaria, which is financed primarily by governments.

Moreover, Novartis and the Medicines for Malaria Venture (with support from the Bill & Melinda Gates Foundation) are starting a new clinical trial next month to test KAF156, a molecule that could form the basis of a new treatment against artemisinin-resistant malaria strains.

At last year's World Economic Forum in Davos, Switzerland, 100 companies (including Novartis) and industry associations signed the Davos Declaration on AMR. Under that commitment, we promised to work together with governments to slow the development of resistance, by increasing our investments in research and development and making high-quality antibiotics available to patients who need them.

The G20's national action plans will, we hope, help us to meet these commitments. But political leaders, too, must marshal the will to turn words into action. We urgently need more resources to monitor resistance, stronger incentives for R&D, and innovative financing mechanisms to ensure widespread access to accurate diagnoses and quality medicines.

The world cannot afford to lose the fight against AMR. Winning it will require large-scale public-private cooperation, underpinned by political leadership that makes global public health a top priority.

The author is chairman of the Novartis board of directors. Project Syndicate

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    亚洲精品久久久久久国产精华液| 亚洲综合另类小说| 成人在线一区二区三区| 国产精品午夜免费| 色一区在线观看| 亚洲成人av在线电影| 日韩欧美国产午夜精品| 国产成人精品影视| 洋洋av久久久久久久一区| 91精品国产色综合久久不卡蜜臀 | 日韩伦理av电影| 欧美性色黄大片| 麻豆国产精品一区二区三区 | 成人手机在线视频| 亚洲欧美日韩一区| 51精品视频一区二区三区| 韩国精品一区二区| 亚洲视频在线一区观看| 欧美日韩电影一区| 国产精品91xxx| 一区二区三区不卡在线观看| 日韩无一区二区| 成人av资源在线| 亚洲国产va精品久久久不卡综合| 日韩写真欧美这视频| 国产91综合网| 亚洲成人动漫在线免费观看| 久久亚洲春色中文字幕久久久| 99久久伊人久久99| 免费成人在线网站| 一区在线观看免费| 欧美成人乱码一区二区三区| 91丨porny丨户外露出| 美女视频黄 久久| 亚洲三级在线免费观看| 欧美成人精精品一区二区频| av不卡免费在线观看| 免费人成黄页网站在线一区二区 | 亚洲主播在线播放| 久久亚洲私人国产精品va媚药| 一本久道久久综合中文字幕| 久久精品国产久精国产爱| 亚洲色图制服诱惑| 精品久久久久久久久久久久久久久| 91丝袜美女网| 国内精品国产成人| 午夜av一区二区三区| 中文字幕在线观看一区二区| 日韩午夜精品电影| 日本二三区不卡| 国产高清不卡二三区| 日韩国产欧美在线视频| 一色桃子久久精品亚洲| 26uuu久久天堂性欧美| 欧美欧美欧美欧美首页| 99视频精品免费视频| 韩国v欧美v亚洲v日本v| 亚洲成人在线免费| 亚洲素人一区二区| 亚洲国产成人私人影院tom| 日韩欧美一级精品久久| 欧美一a一片一级一片| 成人高清视频免费观看| 激情综合色综合久久综合| 亚洲va天堂va国产va久| 亚洲色图另类专区| 国产精品色噜噜| 久久噜噜亚洲综合| 欧美一二三四区在线| 欧美色手机在线观看| 99re这里都是精品| 国产aⅴ综合色| 精品系列免费在线观看| 日韩一区精品视频| 一区二区三区在线观看视频| 国产精品视频yy9299一区| 久久久亚洲午夜电影| 精品国产乱码久久久久久1区2区 | 91麻豆精品国产91久久久久久 | 久久99国产精品久久99果冻传媒| 亚洲成人综合视频| 亚洲一区二区三区国产| 亚洲激情图片一区| 亚洲人成网站精品片在线观看| 欧美国产精品v| 国产欧美日韩久久| 国产亚洲欧洲997久久综合 | www.亚洲国产| 成人一级片网址| 成人sese在线| 成人av电影免费在线播放| 成人黄色一级视频| 成人午夜av电影| 成人毛片视频在线观看| 成人免费观看男女羞羞视频| 26uuu色噜噜精品一区| 欧美成人乱码一区二区三区| 欧美第一区第二区| 欧美成人一区二区三区片免费 | 国产欧美一区二区精品性色超碰| 亚洲精品在线免费播放| 精品国产凹凸成av人导航| 欧美变态凌虐bdsm| 精品国产一区二区三区av性色| 精品久久久久久久久久久久久久久 | 精品欧美一区二区三区精品久久| 日韩欧美高清一区| 精品欧美乱码久久久久久1区2区| 精品国产3级a| 国产欧美综合色| 国产精品久久看| 一区二区三区在线观看视频 | 精品亚洲aⅴ乱码一区二区三区| 精品无人码麻豆乱码1区2区| 国产自产2019最新不卡| 国产传媒一区在线| youjizz久久| 在线亚洲高清视频| 欧美精选午夜久久久乱码6080| 欧美一区2区视频在线观看| 欧美一区二区观看视频| 2021国产精品久久精品| 国产欧美日韩精品在线| 亚洲欧美另类图片小说| 亚洲成人动漫在线观看| 久久不见久久见中文字幕免费| 国产精品自拍三区| 99视频精品全部免费在线| 欧美亚洲综合一区| 欧美videos中文字幕| 中文字幕av一区二区三区免费看 | 亚洲精品中文在线观看| 午夜精品爽啪视频| 久久精品国产精品亚洲红杏| 国产精品996| 在线观看日韩精品| 欧美一区二区在线播放| 久久一区二区三区国产精品| 国产精品久久久久久久久图文区| 亚洲国产人成综合网站| 美女久久久精品| 99热在这里有精品免费| 67194成人在线观看| 国产亚洲欧美中文| 洋洋av久久久久久久一区| 久久99久久久久久久久久久| 成人高清免费观看| 777奇米成人网| 国产欧美日韩卡一| 亚洲v中文字幕| 国产福利一区在线| 欧美视频一区二区三区在线观看| 欧美大尺度电影在线| 亚洲欧洲精品一区二区精品久久久| 亚洲高清久久久| 国产精品一区二区免费不卡| 色偷偷久久人人79超碰人人澡| 日韩欧美一区在线| 日韩一区中文字幕| 日韩av一区二区在线影视| 成人午夜在线免费| 欧美精品1区2区| 国产精品久久久久国产精品日日| 亚洲成人免费在线| 国产91高潮流白浆在线麻豆 | 成人av网在线| 日韩一区二区在线观看视频 | 亚洲私人黄色宅男| 久久不见久久见免费视频7| 日本丶国产丶欧美色综合| 久久色中文字幕| 亚洲va欧美va天堂v国产综合| 成人午夜av影视| 欧美大片顶级少妇| 亚洲国产精品久久艾草纯爱| 国产传媒欧美日韩成人| 欧美美女一区二区三区| 国产精品电影院| 韩国毛片一区二区三区| 欧美日韩一区二区三区四区| 中文av一区二区| 精品一区二区三区在线视频| 欧美色精品天天在线观看视频| 中文文精品字幕一区二区| 奇米在线7777在线精品| 91九色最新地址| 中文字幕+乱码+中文字幕一区| 蜜桃视频免费观看一区| 欧美撒尿777hd撒尿| 国产精品夫妻自拍| 国产九九视频一区二区三区| 日韩一卡二卡三卡四卡| 亚洲在线观看免费| a美女胸又www黄视频久久| 精品国精品自拍自在线| 日韩av一区二区在线影视| 欧美影视一区在线| 亚洲精品国产成人久久av盗摄| 国产成人精品综合在线观看| 精品国产免费一区二区三区四区|